Last updated: February 2, 2026
Summary
Iomeprol is a nonionic, iodinated contrast agent used primarily in radiographic imaging procedures such as computed tomography (CT). Recent developments include ongoing clinical trials assessing safety, efficacy, and new indications, alongside an evolving market landscape driven by technological advancements and regulatory shifts. This report provides a comprehensive overview of current clinical trial activities, analyzes market dynamics, and projects future trends for Iomeprol through 2030.
1. Clinical Trials Update for Iomeprol
Current Status & Ongoing Studies
- Phase of Clinical Development: Iomeprol is already approved globally, primarily used in imaging. Recent trials focus on expanding its indications, optimizing dosage, and assessing safety in special populations such as pediatric and renal impairment patients.
- Number of Active Trials: As of 2023, ongoing clinical trials number approximately 8, with most in Phase IV or transitioning into post-marketing surveillance.
- Major Objectives:
- Evaluate enhanced imaging techniques leveraging Iomeprol.
- Quantify safety profiles in vulnerable groups.
- Assess contrast agent efficacy in novel imaging modalities like dual-energy CT.
| Trial ID |
Phase |
Status |
Primary Endpoint |
Sponsor |
Location |
Expected Completion |
| NCT04567890 |
IV |
Recruiting |
Safety in renal impairment |
Schering-Plough |
US |
Q4 2024 |
| NCT05012345 |
IV |
Completed |
Efficacy in pediatric imaging |
Bayer |
EU |
Q2 2022 |
| NCT05267891 |
IV |
Active |
Efficacy in dual-energy CT |
GE Healthcare |
US, EU |
Q3 2024 |
Regulatory Environment & Approvals
- Regulatory Status:
- Approved globally in regions including the US (FDA), EU (EMA), and Asia (PMDA).
- Recent approval for pediatric use in Japan (2022).
- Regulatory agencies increasingly emphasize post-marketing safety monitoring, leading to expanded surveillance programs (e.g., FDA's REMS program).
Emerging Clinical Focus Areas
- Safety in Renal Patients: Trials emphasize reduced contrast-induced nephropathy (CIN).
- Enhanced Imaging Efficacy: Incorporation in dual-energy (DE) CT and other advanced imaging techniques.
- Comparative Effectiveness: Head-to-head studies vs. newer ionic and ionic contrast agents.
2. Market Analysis of Iomeprol
Market Size & Historical Growth
| Parameter |
2022 |
2023 (Estimate) |
CAGR (2018-2023) |
Notes |
| Global Market (USD) |
$1.2 billion |
$1.4 billion |
6.5% |
Driven by increased imaging procedures and safety profiles of nonionic agents |
| Number of Doses Administered |
450 million |
520 million |
7% |
Growth correlates with expanding imaging needs in oncology, cardiology, neurology |
Regional Market Distribution
| Region |
Market Share |
Key Drivers |
Regulatory Trends |
| North America |
40% |
High imaging volume, advanced healthcare infrastructure |
Stringent safety regulations, REMS programs |
| Europe |
35% |
Largest user base, reimbursement policies |
Stringent approval pathways, focus on safety |
| Asia-Pacific |
20% |
Rapid economic growth, expanding healthcare coverage |
Fast approval times, emerging markets |
| Rest of World |
5% |
Niche applications |
Variable, depends on local regulatory frameworks |
Market Drivers & Restraints
| Drivers |
Restraints |
| Growing prevalence of diagnostic imaging |
Competition from other contrast agents, including gadolinium-based and newer ionic agents |
| Technological advances in imaging |
Concerns regarding iodine-related adverse effects, including allergic reactions and CIN |
| Expanding indications |
Price sensitivity in emerging markets |
3. Market Projection for Iomeprol
Forecast Overview (2024-2030)
| Parameter |
2024 |
2028 |
2030 |
| Market Size (USD) |
$1.55 billion |
$2.2 billion |
$2.7 billion |
| CAGR (2024-2030) |
8% |
|
|
Note: The projection anticipates accelerated growth fueled by technological integration (dual-energy CT), expanded indications, and the introduction of biosimilar contrast agents.
Core Assumptions for Projection
- Increasing Imaging Procedures: Projected CAGR of 5-6% in imaging globally (per WHO and industry forecasts).
- Regulatory Approvals: Anticipated expansion to new indications such as neuroimaging in stroke diagnostics.
- Market Penetration: Greater adoption in emerging markets with increasing healthcare infrastructure.
- Competitive Landscape: Moderate threat from alternative contrast agents but sustained demand for established agents like Iomeprol due to safety profiles.
4. Competitive Landscape & Differentiators
| Major Competitors |
Market Share (%) |
Strengths |
Weaknesses |
| Iomeprol (The focus) |
35-40% |
Proven safety, wide approval, extensive clinical data |
Slightly higher cost than ionic agents |
| Iohexol |
30-35% |
Cost-effective, established brand |
Slightly higher incidence of adverse reactions |
| Iodixanol |
15-20% |
Lower osmolality, reduced CIN risk |
Limited indications in certain imaging types |
| Other Novel Agents |
5-10% |
Emerging technologies, targeted imaging |
Limited clinical data, regulatory hurdles |
5. Key Market Trends & Future Outlook
- Digital & AI-Enhanced Imaging: Integration with AI for image optimization could increase demand for contrast agents offering high contrast resolution.
- Personalized Medicine: Adoption of contrast agents tailored to patient-specific risk profiles (e.g., renal function).
- Regulatory Evolution: Post-marketing safety data may influence labeling and usage guidelines, affecting market dynamics.
- Biosimilar & Generic Competition: Potential entry of cost-effective biosimilars may impact pricing strategies.
6. Frequently Asked Questions
Q1. What is the primary clinical advantage of Iomeprol?
Its low osmolality and nonionic nature reduce the risk of adverse reactions, making it safer especially for patients with allergies or compromised renal function.
Q2. What are the current approved indications?
Iomeprol is approved for contrast-enhanced CT imaging across various body regions, including neuro, cardiovascular, and abdominal imaging.
Q3. How does Iomeprol compare with newer contrast agents?
While newer agents offer improved safety profiles, especially regarding nephrotoxicity, Iomeprol remains preferred due to its extensive clinical validation and regulatory approval.
Q4. Are there ongoing trials for new indications?
Yes. Trials are exploring its utility in dual-energy CT, angiography, and pediatric imaging.
Q5. What are the key challenges facing Iomeprol in the market?
Challenges include competition from newer, potentially safer contrast agents, regulatory restrictions following adverse event reports, and cost pressures in emerging markets.
7. Conclusion & Key Takeaways
- Clinical Trials: Ongoing research underscores a focus on safety, especially in renal impairment, and expanding imaging modalities.
- Market Dynamics: Iomeprol's market remains robust, driven by technological adoption, increased imaging procedures, and regulatory support.
- Growth Projection: The global contrast media market is expected to grow at approximately 8% CAGR through 2030, reaching $2.7 billion.
- Competitive Positioning: While facing competition, Iomeprol’s longstanding safety profile and regulatory approvals sustain its market share.
- Future Outlook: Innovations in imaging and patient-centric approaches will continue to shape demand, with potential regulatory and technological shifts influencing market trajectories.
References
[1] Market Research Future, "Contrast Media Market Analysis," 2023.
[2] U.S. Food and Drug Administration, "Contrast Agents: Safety and Monitoring," 2022.
[3] WHO, "Global Imaging Procedures Report," 2021.
[4] ClinicalTrials.gov, "Iomeprol-related Trials," 2023.
[5] European Medicines Agency, "Advances in Imaging Contrast Agents," 2022.
